CoChat
Sign Up
Cited by 22

The DOI matches its Crossref record.

Correlation analysis and clinical significance of CA125, HE4, DDI, and FDP in type II epithelial ovarian cancer

Qiao, Li, Chen, Xinhua, Xi, Xuxia, Chen, Xueqin, Zhang, Pengpeng, Dong, Hua, Wu, Xiaohua, Chen, Xiaojun·2020·Medicine
DOI 10.1097/md.0000000000023329PMC PMC7717762
Open this paper in CoChat — free account

Abstract

Ovarian cancer is one of the common female malignant tumors. The early diagnosis and treatment of ovarian cancer has been a research hotspot. Therefore, we aimed to investigate the correlations between the levels of carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4), D-dimer (DDI), and fibrinogen degradation product (FDP) in patients with type II epithelial ovarian cancer. From January 2018 to January 2019, a total of 952 patients who underwent initial surgery for epithelial ovarian cancer were enrolled in this study. Peripheral venous blood was taken before operation, and the levels of CA125, HE4, DDI, and FDP were tested. The correlations between the levels of CA125, HE4, DDI, and FDP and other clinical indicators (such as presence or absence of chemotherapy, surgical conditions) were analyzed. The level of DDI or FDP was statistically associated with age, chemotherapy, Figo staging, surgical procedure, HE4 level, and CA125 level, respectively. Moreover, the Figo staging was statistically correlated with the levels of HE4 and CA125. Besides, we found the levels of CA125 and HE4 were positively correlated with the levels of DDI and FDP. The levels of CA125 and HE4 are the traditional detection indexes for patients with type II epithelial ovarian cancer, and these 2 indicators reflected the degree of disease and prognosis. The levels of DDI and FDP were closely related to the levels of CA125 and HE4 in type II epithelial ovarian cancer, and they also helped to assess the prognosis of epithelial ovarian cancer. Further larger-scale prospective cohort studies are warranted to determine these associations in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000023329

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 26

  1. Shetty, 2019, Imaging and differential diagnosis of ovarian cancer, Semin Ultrasound Ct Mri, 40, 302, 10.1053/j.sult.2019.04.002 · DOI
  2. Jelovac, 2011, Recent progress in the diagnosis and treatment of ovarian cancer, CA, 61, 183
  3. Johnson, 2009, The standard of perfection: thoughts about the laying Hen model of ovarian cancer, Cancer Prev Res, 2, 97, 10.1158/1940-6207.CAPR-08-0244 · DOI
  4. Nicoletta, 2006, Ovarian cancer, Oncol Hematol, 60, 159
  5. Desai, 2014, Epithelial ovarian cancer: an overview, World J Transl Med, 3, 1, 10.5528/wjtm.v3.i1.1 · DOI
  6. Coleman, 2013, Latest research and treatment of advanced-stage epithelial ovarian cancer, Nat Rev Clin Oncol, 10, 211, 10.1038/nrclinonc.2013.5 · DOI
  7. Koshiyama, 2014, Recent concepts of ovarian carcinogenesis: type I and type II, J Biomed Biotechnol, 2014, 934261
  8. Kaku, 2003, Histological classification of ovarian cancer, Med Electron Microsc, 36, 9, 10.1007/s007950300002 · DOI
  9. 2018, Clinical value of automated fibrin generation markers in patients with septic shock: A SepsiCoag ancillary study, Bri J Haematol, 183, 636, 10.1111/bjh.15576 · DOI
  10. Olson, 2015, D-dimer: an overview of hemostasis and fibrinolysis, assays, and clinical applications, Adv Clin Chem, 69, 1, 10.1016/bs.acc.2014.12.001 · DOI
  11. Victor, 1971, Detection of serum fibrinogen and fibrin degradation products: comparison of six technics using purified products and application in clinical studies, Am J Med, 51, 71, 10.1016/0002-9343(71)90325-1 · DOI
  12. Planner, 2010, The hypercoagulable state and pulmonary embolism in patients with ovarian carcinoma, Aust N Z J Obstet Gynaecol, 18, 209, 10.1111/j.1479-828X.1978.tb00052.x · DOI
  13. Zhen, 2014, Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis, Molec Clin Oncol, 2, 559, 10.3892/mco.2014.279 · DOI
  14. Speeckaert, 2013, Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker, Adv Clin Chem, 59, 1, 10.1016/B978-0-12-405211-6.00001-2 · DOI
  15. Wang, 2015, Predictive value of plasma D-dimer levels in patients with advanced non-small-cell lung cancer, Onco Targets Ther, 8, 805, 10.2147/OTT.S78154 · DOI
  16. Antoniou, 2006, Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer, Lung Cancer, 53, 205, 10.1016/j.lungcan.2006.03.015 · DOI
  17. Yan, 2018, Correlation analysis between D-dimer FDP and PLT and prognosis of epithelial ovarian cancer, Anhui Med J, 39, 1171
  18. Diaz, 2013, Venous throm-boembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival, Gynecol Oncol, 131, 541, 10.1016/j.ygyno.2013.09.005 · DOI
  19. Chen, 2007, The role of combined detection of CA125 and D-dimer in the differential diagnosis of ovarian cancer, J Pract Obstetr Gynecol, 23, 475
  20. Gadducci, 1996, Preoperative evaluation of D - dimer and CA125 levels in differentiating benign from malignant ovarian masses, Gynecol Oncol, 60, 197, 10.1006/gyno.1996.0025 · DOI
  21. von Tempelhoff, 1997, Blood coagulation and thrombosis in patients with ovarian malignancy, Thromb Haemost, 77, 456, 10.1055/s-0038-1655988 · DOI
  22. Nagy, 2012, D-dimer as a potential prognostic marker, Pathol Oncol Res, 18, 669, 10.1007/s12253-011-9493-5 · DOI
  23. Mackman, 2007, Role of the extrinsic pathway of blood coagulation in hemostasis and thromhosis, Arteroscler Thromb VascBiol, 27, 1687, 10.1161/ATVBAHA.107.141911 · DOI
  24. Li, 2017, Changes and clinical significance of fibrin degradation products and D-dimer in peripheral blood platelet counts in patients with epithelial ovarian cancer, Anhui Med Pharmaceut J, 38, 288
  25. Iwasaki, 2007, Significance of platelet counts in patients who underwent surgical treatment for lung metastasis, Int Surg, 92, 103
  26. Meng, 2010, Relationship between patients with advanced ovarian cancer serous papillary cystadenocarcinoma and increased platelet count, China J Modern Med, 20, 1575

Cited by

Sorted by citations

Metadata

Authors
Qiao, L., Chen, X., Xi, X., Chen, X., Zhang, P., Dong, H., Wu, X., & Chen, X.
Venue
Medicine
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2020-12-04
Volume
99
Issue
49
Pages
e23329
ISSN
  • 0025-7974
  • 1536-5964
DOI
10.1097/md.0000000000023329
PMC
PMC7717762
Cited by
22
References
0
Language
en
Licence
creativecommons.org/licenses/by-nc/4.0 (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review